Nanoparticles in Antibacterial Therapy: A Systematic Review of Enhanced Efficacy against Intracellular Bacteria
Abstract
High Resolution Image Download MS PowerPoint Slide Intracellular bacterial infections represent a considerable therapeutic challenge due to the ability of pathogens to invade and replicate within host cells, hampering the action of the immune system and the effectiveness of conventional antibiotics. Bacteria such as Mycobacterium tuberculosis, Listeria monocytogenes, and methicillin-resistant Staphylococcus aureus (MRSA), among others, can persist within host cells, allowing them to evade the immune response and develop resistance to antibacterial treatments. A key factor in the persistence of these infections is the ability of bacteria to enter a dormant state, which reduces their susceptibility to antibiotics that affect the dividing cells. Nanotechnology is emerging as a promising solution as nanoparticle-based systems can improve the intracellular penetration of antibiotics, allow their controlled release, and reduce side effects. This review covers the development and efficacy of nanoparticle-encapsulated antibiotics in models of intracellular infections, highlighting the need to further investigate their potential to overcome the barriers of conventional therapies and improve the treatment of these complex infections.
How strong is the evidence?
Evidence Hub reads this as a systematic review. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.